Press releases
These press releases are intended for journalists and analysts/investors.
-
GSK Australia continues bridging skills gap between academic and industry with new cohort of Graduate Researchers
Second year of our Graduate Researcher Program.
Read more -
Enhanced parental leave policy increases support for working parents at GSK Australia and New Zealand
GSK Australia & New Zealand's next evolution of its parental leave policy that ensures inclusive & accessible benefits for all GSK employees
Read more -
TRELEGY® ELLIPTA® listed on PBS for severe asthma
Single inhaler triple therapy for severe asthma reimbursed by the PBS in Australia
Read more -
GSK Australia supports the Australian Red Cross Queensland and New South Wales Flood Appeal
GSK Australia supports the Australian Red Cross Queensland and New South Wales Flood Appeal
Read more -
GSK & ViiV Healthcare: Our commitment to all LGBT+ communities
GSK & ViiV Healthcare: Our commitment to all LGBT+ communities
Read more -
TGA approves Zejula for ovarian cancer providing another option for newly diagnosed women with this deadly disease
GSK Australia welcomes the Therapeutic Goods Administration (TGA) registration of niraparib.
Read more -
Global innovation in intensive care research wins Australian duo GSK Award for Research Excellence
The 2021 GSK Award for Research Excellence was presented at Research Australia’s Health and Medical Research Awards in Sydney.
Read more -
GSK Australia Celebrate Launch of Reconciliation Action Plan
We seek to listen, learn and engage with Aboriginal and Torres Strait Islander peoples to play our part in Australian Reconciliation.
Read more -
Experts map “post-jab” future in GSK-sponsored panel discussion
Today’s discussion was the first in a series of three sessions that will focus on Australia’s post-pandemic future, convened by CEDA.
Read more -
First monoclonal antibody treatment approved for COVID-19 in Australia
GSK Australia and Vir Biotechnology have today welcomed the Therapeutic Goods Administration (TGA) provisional approval of sotrovimab.
Read more -
New shingles vaccine now available in Australia, June 2021
GSK Australia today announced that a new vaccine to help protect against shingles in adults aged 50 years and older
Read more -
GSK Australia reports 2020 results to ASIC, May 2021
GlaxoSmithKline (GSK) Australia has reported its 2020 results to the Australian Securities and Investment Commission
Read more -
GSK and ViiV Support the Uluru Statement from the Heart
GSK and ViiV are also proud to support the From the Heart campaign to raise awareness and understanding of the Uluru Statement
Read more -
Triathlete turned scientist wins major research award for uncovering potential obesity and diabetes treatment
Professor Mark Febbraio wins the GSK Award for Research Excellence in 2020
Read more -
Following decision announced in July, GSK confirms Boronia manufacturing site to close at end of 2022
In July, GSK announced to employees and stakeholders that the Boronia site would exit the GSK manufacturing network
Read more -
GSK welcomes new Meningococcal B program to help protect those most at risk
GSK welcomed the addition of Meningococcal vaccination for Aboriginal and Torres Strait Islander infants to National Immunisation Program
Read more -
Greater flexibility for Australians with severe asthma with reimbursement of at-home, self-administration delivery of NUCALA® (mepolizumab)
GSK announced that a new pre-filled pen for the self-administration of its targeted therapy for severe eosinophilic asthma patients
Read more -
GSK Australia reports 2019 results (excluding Consumer Healthcare) to ASIC
GSK has reported its 2019 results to the Australian Securities and Investment Commission
Read more -
Sanofi and GSK to join forces in unprecedented vaccine collaboration to fight COVID-19
Companies to combine innovative technologies to develop an adjuvanted COVID-19 vaccine
Read more -
GSK Australia now holds the marketing authorisation for Zejula (niraparib) for ovarian cancer
GSK now holds the marketing authorisation for Zejula (niraparib) for ovarian cancer
Read more
-
About us
We are a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer.
-
Products
We make a wide range of prescription medicines, vaccines and consumer healthcare products.
-
Careers
GSK is a place where talented people do amazing things. Where you are encouraged to be you and create a meaningful impact.
-
Research and development
Science can improve health and well-being in so many ways, from the development of everyday convenience healthcare products.
